Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF MAY 31, 2015 FBO #4937
SOLICITATION NOTICE

68 -- Assays

Notice Date
5/29/2015
 
Notice Type
Presolicitation
 
NAICS
325414 — Biological Product (except Diagnostic) Manufacturing
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
 
ZIP Code
20892
 
Solicitation Number
HHS-NIH-NIDA-SSSA-NOI-15-284
 
Archive Date
6/24/2015
 
Point of Contact
Andrea McGee, Phone: 3014358781
 
E-Mail Address
amcgee@nida.nih.gov
(amcgee@nida.nih.gov)
 
Small Business Set-Aside
Total Small Business
 
Description
SOLICITATION NUMBER: HHS-NIH-NIDA-SSSA-NOI-15-284 TITLE: Assays INTRODUCTION This is a pre-solicitation non-competitive (notice of intent) synopsis to award a contract without providing for full or open competition (including brand-name). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute on Drug Abuse (NIDA), Consolidated Station Support and Simplified Acquisitions (CSS/SA) Branch intends to negotiate and award a purchase order to CISBIO USA for small molecules without providing for full and open competition (including brand-name). NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE This acquisition is unrestricted. The associated NAICS code 325414 with a size standard of 500 employees. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the through Federal Acquisition Circular (FAC) 2005-80 effective April 10, 2015. This acquisition is for a commercial item or service and is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures. This acquisition is NOT expected to exceed the simplified acquisition threshold. STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1. DESCRIPTION OF REQUIREMENT Purpose and Objectives: The purpose of this requirement is to acquire the purchase of proprietary custom antibodies, buffers, and blocking reagents required for our approved assay project. Project Description: The Tox21 group of National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI) requires a reagent named "HTRF® Phospho-H2A.X (S139) Assay" to run H2A.X assay against Tox21 Library collections. This will be used to screen the Tox21 10K library with an assay for DNA damage. The assay works by detecting the phosphorylation of histone H2AX by labeling antibodies with donor and acceptor fluors (europium cryptate and d2) to enable homogenous detection in a high throughput environment using Cisbio's HTRF technology. Currently, the only technology available for pH2AX detection is immunofluorescence, which requires many incubation and wash steps. HTRF® is a homogeneous and non radio-isotopic technology. This HTRF technology has been developed and also successfully used for our online validation for this homogenous (no wash steps) DNA damage detection assay that was just approved by our review group. When DNA double strand breaks occur, histone H2AX is phosphorylated and moves to the site of the damage. This assay will be used to CHO cells as a marker for DNA damage. Homogenous assays, like HTRF, are key to efficient and effective screening. Our Tox21 research group, as well as other NCATS Biology groups, has used this Cisbio HTRF technology for several large screens in 1536 well format, with high reproducibility and low false positives, compared to other technologies. For example, the HTRF TNF alpha assay was used to screen the LOPAC and FDA libraries in 1536 well format with great success. We will use this assay to screen compounds from EPA/NTP/FDA. This is the Tox21 collaboration work between NCGC and NTP/EPA/FDA. Specifically, NCATS requires the following: Histone2 HTRF assay 10K tests Qty. 10 Delivery/Period of Performance: 30 Days ARO CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, CISBIO is the only vendor in the current market place that can provide the unique services required by the of National Center for Advancing Translational Sciences. In accordance with FAR part 10, extensive market research was conducted to reach this determination. Specifically, a small business sources sought notice was posted to FedBizOpps referencing the above detailed requirements and no responses were received. Therefore, only CISBIO USA is capable of meeting the needs of this requirement. The intended source is: Cisbio USA 135 South Road Bedford, MA 01730 CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses shall be submitted no later than June 9, 2015 at 4:30pm EST. Responses may be submitted electronically to amcgee@nih.gov or by U.S. mail to the National Institute of Drug Abuse (NIDA), Station Support / Simplified Acquisition Branch (SS/SA), Attention: Andrea McGee. Fax responses will not be accepted.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/HHS-NIH-NIDA-SSSA-NOI-15-284/listing.html)
 
Place of Performance
Address: 9800 Medical Center Drive, Rockville, Maryland, 20850, United States
Zip Code: 20850
 
Record
SN03747269-W 20150531/150529235332-5e468df3352c6302a262e83ddea57613 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.